Investor

Seido Capital

Montréal, QC, Canada

The 50 · Pre-seed to Series B · Life Sciences, Healthtech

Early and growth-stage VC (pre-seed to Series B) building global healthcare leaders from locally disruptive technologies. MedTech, Biotech, AI in Health. North America primary focus.

Type: The 50
Stage: Pre-seed to Series B
AUM: US$140M
Other offices: Vancouver · Brussels
Source: The 50: Canadian VC Ecosystem Guide 2026

Investment thesis

Early and growth-stage VC (pre-seed to Series B) building global healthcare leaders from locally disruptive technologies. MedTech, Biotech, AI in Health. North America primary focus.

What makes them unique

Exit-driven mindset with deep life-science expertise. Start due diligence from the exit backwards. 50+ investments, 30+ exits, targeting 7-10x cash returns.

Team

Olivier Bélenger (Cofounder & Managing Partner)
Théo Risopoulos (Cofounder & GP)
Patricia Escoffier (Principal)
Michel Lussier (Partner)
Gabrielle Girouard (PhD Analyst)

Select portfolio

Henogen (acquired by Novasep/Thermo Fisher for €715M)Ogeda (acquired by Astellas for €800M)MaSTherCell (acquired by Catalent for €315M)CluePoints (acquired by EQT at €700M+ - 33.2x MOIC, ~50% IRR)